Several cancer drugs taken as a single daily pill have now replaced what used to require monthly or quarterly intravenous infusions or injections at a clinic. The most prominent examples include Orgovyx (relugolix), approved by the FDA in December 2020 as the first oral androgen deprivation therapy for advanced prostate cancer, and Inluriyo (imlunestrant), approved in September 2025 as the first oral estrogen receptor degrader for certain types of advanced breast cancer. Both drugs allow patients to take a pill at home each morning instead of traveling to an infusion center for treatments that could consume hours of their day.
For the millions of people managing both cancer and cognitive decline — or for caregivers coordinating complex medical schedules — this shift from IV infusions to oral pills is more than a matter of convenience. Monthly clinic visits for injections create logistical burdens that fall hardest on older adults, particularly those living with dementia or mild cognitive impairment who depend on others for transportation and supervision during treatment. A once-daily pill taken at the kitchen table changes the calculus of cancer care in ways that ripple through every aspect of daily life. This article examines the specific drugs that have made this transition possible, the clinical evidence behind them, how they compare to the injections they replace, the practical considerations for patients with cognitive challenges, and what emerging research from Stanford suggests about the future of converting IV drugs to oral form.
Table of Contents
- Which Cancer Drug Pill Taken Once Daily Has Replaced Monthly IV Infusions for Prostate Cancer?
- How Inluriyo Changed Breast Cancer Treatment by Eliminating Monthly Injections
- Oral Cancer Pills in Lung Cancer and the Push Toward Injection-Free Regimens
- What Caregivers and Patients With Cognitive Decline Should Know About Daily Cancer Pills
- Side Effects, Drug Interactions, and Limitations of Oral Cancer Therapies
- Stanford’s Research Into Converting Any IV Cancer Drug to a Pill
- Where Oral Cancer Therapy Is Headed
- Conclusion
- Frequently Asked Questions
Which Cancer Drug Pill Taken Once Daily Has Replaced Monthly IV Infusions for Prostate Cancer?
Orgovyx (relugolix) was the first oral medication to replace the monthly or quarterly injections that had been the standard of care in advanced prostate cancer for decades. Before Orgovyx, most men with advanced prostate cancer received Lupron (leuprolide) injections every one to three months at a clinic. Lupron works by suppressing testosterone, which fuels prostate cancer growth, but it requires a healthcare provider to administer the injection and carries well-documented cardiovascular risks. Orgovyx achieves the same testosterone suppression through a different mechanism — blocking the gonadotropin-releasing hormone receptor — and does so with a single pill taken once daily at home after a three-pill loading dose on the first day. The HERO trial, which led to Orgovyx’s approval, demonstrated that 96.7 percent of men taking Orgovyx achieved and sustained castrate-level testosterone from Day 29 through Week 48, compared to 88.8 percent of men receiving leuprolide injections. That modest numerical difference in the primary endpoint understates a more striking finding: the risk of major adverse cardiovascular events was 54 percent lower with Orgovyx compared to leuprolide.
For older men who may already be managing heart disease alongside their cancer — a population that overlaps significantly with those at risk for vascular dementia — that cardiovascular advantage is not a footnote. It is a central consideration. Another distinction matters for patients and caregivers thinking about long-term planning. When men stop taking Orgovyx, their testosterone levels return to normal within months. Lupron, by contrast, can suppress testosterone for many months after the last injection, making it harder to predict recovery timelines. In July 2024, NICE in the United Kingdom approved Orgovyx as a take-at-home prostate cancer pill, further validating the shift away from injection-dependent treatment models.
How Inluriyo Changed Breast Cancer Treatment by Eliminating Monthly Injections
For women with estrogen receptor-positive, HER2-negative advanced breast cancer that carries an ESR1 mutation, the standard treatment after initial endocrine therapy had long been fulvestrant, sold under the brand name Faslodex. Fulvestrant works by degrading estrogen receptors on cancer cells, but it has a stubborn limitation that researchers spent years trying to overcome: it cannot be taken orally. Every month, patients had to visit a clinic for two intramuscular injections, one in each buttock, a process that is uncomfortable and time-consuming. On September 25, 2025, the FDA approved Inluriyo (imlunestrant), developed by Eli Lilly, as the first oral selective estrogen receptor degrader, or SERD. The dosage is 400 milligrams once daily — two tablets taken on an empty stomach. The EMBER-3 trial showed that imlunestrant reduced the risk of disease progression or death by 38 percent compared to standard endocrine therapy, which included either fulvestrant or exemestane.
Median progression-free survival was 5.5 months with imlunestrant versus 3.8 months with standard therapy. Those numbers are modest in absolute terms, and oncologists have been candid about the fact that this drug is not a cure. However, the combination of improved efficacy and the elimination of monthly injection visits represents a meaningful quality-of-life gain, particularly for patients whose cancer has already progressed through at least one prior line of endocrine therapy. There is an important caveat, however. Inluriyo is specifically indicated for patients whose tumors carry an ESR1 mutation, which is detected through a blood test or tumor biopsy. Not all ER-positive breast cancers have this mutation, so this pill does not replace fulvestrant for every patient currently receiving those injections. Women whose tumors lack the ESR1 mutation may still need to continue with injectable fulvestrant or explore other treatment options with their oncologist.
Oral Cancer Pills in Lung Cancer and the Push Toward Injection-Free Regimens
The movement from infusion to oral treatment extends beyond breast and prostate cancer. In August 2024, the FDA approved Lazcluze (lazertinib) in combination with Rybrevant (amivantamab) for EGFR-mutated non-small cell lung cancer. Lazertinib is taken as a 240-milligram oral pill once daily, and the MARIPOSA trial demonstrated a median progression-free survival of 23.7 months with the combination, compared to 16.6 months for osimertinib alone. That seven-month improvement in progression-free survival is among the more substantial gains seen in recent lung cancer trials. The practical picture for this combination is more complicated than with Orgovyx or Inluriyo, though.
While lazertinib itself is a daily oral pill, its combination partner amivantamab was originally an intravenous infusion that could take several hours to administer. That changed in February 2026, when the FDA approved Rybrevant Faspro, a subcutaneous version of amivantamab that reduces administration time from hours to minutes. The injection is still required, but the shift from a lengthy IV infusion to a brief subcutaneous shot — combined with the daily oral lazertinib — represents a significant reduction in the treatment burden. This example illustrates an important nuance: the transition from IV to oral is rarely all-or-nothing. Many modern cancer regimens combine oral pills with less burdensome forms of injectable therapy, and patients should understand the full picture of their treatment schedule rather than assuming that an oral component means they will never need to visit a clinic.
What Caregivers and Patients With Cognitive Decline Should Know About Daily Cancer Pills
The shift to oral cancer therapy creates a different kind of challenge for patients with dementia or cognitive impairment. Monthly clinic visits, while burdensome, come with built-in medical supervision: a nurse administers the drug, monitors for immediate reactions, and confirms the treatment was received. A daily pill taken at home transfers that responsibility to the patient or their caregiver. For someone with memory loss, executive function difficulties, or the apathy that often accompanies frontotemporal or Alzheimer’s-type dementia, remembering to take a cancer pill every morning — on an empty stomach, in the case of Inluriyo — is not a trivial ask. Pill organizers, phone alarms, and caregiver-administered medication routines become essential infrastructure.
Some caregivers have found that linking the cancer pill to an existing daily habit, like morning coffee or a blood pressure medication, improves adherence. Pharmacists can also help by synchronizing refill dates across all medications to reduce the number of trips and decision points. For Orgovyx specifically, the three-pill loading dose on Day 1 requires clear communication with whoever is managing the patient’s medications, because a missed or doubled loading dose could affect the drug’s initial effectiveness. The tradeoff is real but, for most patients, favorable. Missing a single daily dose of an oral cancer drug is generally less consequential than missing an entire monthly injection appointment — which might happen if transportation falls through, if the patient becomes agitated on the day of the visit, or if a caregiver is unavailable. Oral therapy provides more flexibility and more chances to get it right across any given month.
Side Effects, Drug Interactions, and Limitations of Oral Cancer Therapies
Oral cancer drugs are not inherently gentler than their injectable counterparts. Orgovyx can cause hot flashes, fatigue, musculoskeletal pain, and diarrhea. Inluriyo carries risks of nausea, fatigue, joint pain, and elevated liver enzymes. Lazertinib, in combination with amivantamab, has been associated with skin rash, diarrhea, and nail changes. These side effects occur at home, away from the immediate observation of a medical team, which means patients and caregivers need to know what warrants a phone call to the oncologist and what can be managed with supportive care. Drug interactions are another concern that intensifies with oral medications. Many older adults with cancer are also taking medications for hypertension, diabetes, depression, or — relevant to readers of this site — cholinesterase inhibitors like donepezil or memantine for dementia.
Oral cancer drugs are metabolized through the liver and gut, and some interact with common medications or even with grapefruit juice. Orgovyx, for instance, should not be co-administered with certain drugs that affect a liver enzyme called CYP3A, because they can alter how much of the drug reaches the bloodstream. A pharmacist review of the full medication list is not optional; it is a safety requirement. There is also the matter of cost and insurance coverage. Oral cancer drugs are often classified under the pharmacy benefit rather than the medical benefit of insurance plans, which can result in different copay structures. Some patients find that their out-of-pocket cost for a daily oral pill is actually higher than it was for a monthly injection administered in a clinic setting. Manufacturer assistance programs exist for both Orgovyx and Inluriyo, but navigating them adds another layer of administrative work that often falls on caregivers who are already stretched thin.
Stanford’s Research Into Converting Any IV Cancer Drug to a Pill
In October 2024, Stanford researchers published findings on a molecular tagging strategy designed to convert virtually any intravenous drug into an oral form. Their approach attaches a small molecular tag to existing IV drugs, allowing them to survive the harsh environment of the digestive system and pass through the gut lining into the bloodstream. In mouse studies, their oral version of paclitaxel — one of the most widely prescribed IV chemotherapy drugs, used in breast, ovarian, and lung cancers — actually performed better than the standard IV dose.
This research is still preclinical, meaning it has only been tested in mice and has not yet entered human clinical trials. The path from promising mouse data to an approved human drug typically takes many years and most candidates do not make it. Still, the concept is significant because it does not target a single drug but rather offers a platform technology that could theoretically be applied to many existing IV chemotherapies. If it eventually works in humans, it could transform the treatment landscape far beyond the individual drugs discussed in this article.
Where Oral Cancer Therapy Is Headed
The trend toward oral cancer treatment is accelerating. Pharmaceutical companies have strong incentives to develop pill-based alternatives: patients prefer them, adherence data can be collected through smart pill bottles and digital health tools, and the manufacturing logistics are simpler than those for injectable biologics. Several additional oral SERDs and next-generation hormone therapies are in late-stage clinical trials, and the success of Orgovyx and Inluriyo has demonstrated to regulators and insurers that oral alternatives can match or exceed the efficacy of their injectable predecessors.
For families managing the intersection of cancer and dementia, these developments offer cautious optimism. Every treatment that can be simplified — from an hours-long infusion center visit to a pill swallowed at the breakfast table — reduces the cognitive and logistical demands on patients and caregivers alike. The drugs are not perfect, the side effects are real, and the coordination required to manage them safely at home should not be underestimated. But the direction is clear, and for millions of patients, the infusion chair is becoming optional.
Conclusion
The shift from monthly IV infusions to once-daily oral cancer pills represents one of the most patient-centered advances in recent oncology. Orgovyx replaced decades of injectable hormone therapy for prostate cancer with a single daily tablet that showed 54 percent fewer major cardiovascular events. Inluriyo became the first oral estrogen receptor degrader for ESR1-mutated breast cancer, freeing patients from monthly fulvestrant injections. Lazertinib added an oral daily option for EGFR-mutated lung cancer.
And Stanford’s early-stage research hints at a future where many more IV chemotherapies could be reformulated as pills. For patients living with cognitive decline and their caregivers, these oral therapies remove significant barriers to cancer treatment — fewer clinic trips, simpler scheduling, and reduced disruption to daily routines. The tradeoffs include the need for reliable daily medication management, awareness of drug interactions, and attention to side effects that now manifest at home rather than under clinical observation. Anyone considering a transition from injectable to oral cancer therapy should have a detailed conversation with their oncologist and pharmacist, with the full medication list in hand, to ensure the switch is safe and appropriate for their specific situation.
Frequently Asked Questions
Can I switch from Lupron injections to Orgovyx on my own?
No. Switching from leuprolide (Lupron) to Orgovyx (relugolix) must be done under the supervision of your oncologist. The timing of the transition matters, and the three-pill loading dose on Day 1 of Orgovyx needs to be coordinated with the schedule of your last injection to avoid a gap or overlap in testosterone suppression.
Is Inluriyo available for all types of breast cancer?
Inluriyo is specifically approved for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer who have already progressed on at least one line of endocrine therapy. If the tumor does not carry an ESR1 mutation, Inluriyo is not indicated, and fulvestrant injections or other therapies may still be necessary.
Does taking an oral cancer pill at home mean fewer doctor visits overall?
It means fewer visits for drug administration, but regular monitoring appointments — including blood work, imaging, and clinical assessments — are still required. Oral cancer drugs still need medical oversight; the difference is that treatment itself happens at home rather than in a clinic chair.
Are oral cancer drugs safer than IV infusions?
Not necessarily. Oral cancer drugs carry their own side effect profiles and drug interaction risks. The safety advantage is primarily logistical — fewer infusion-related reactions and reduced exposure to clinic-based infections — rather than a fundamental difference in the drugs’ toxicity. Each patient’s risk profile determines which form is more appropriate.
What if a patient with dementia forgets to take their daily cancer pill?
Missed doses should be handled according to the specific prescribing information for each drug. Generally, a single missed dose is not an emergency, but consistent non-adherence can undermine treatment effectiveness. Caregivers should work with the oncology team to establish a medication management plan, which may include pill organizers, alarms, or supervised administration.
When might Stanford’s IV-to-pill technology become available for patients?
The molecular tagging technology published in October 2024 is still in the preclinical stage, meaning it has only been tested in mice. Human clinical trials have not yet begun, and the typical timeline from preclinical research to FDA approval — if it succeeds — is many years. It is a promising area of research but not a near-term treatment option.
